These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9608763)

  • 1. [Dopamine receptors and dyskinesias].
    Linazasoro G
    Neurologia; 1998 Apr; 13(4):206-7. PubMed ID: 9608763
    [No Abstract]   [Full Text] [Related]  

  • 2. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on antiparkinsonian agents.
    Weiner M
    Geriatrics; 1982 Sep; 37(9):81-4, 89-91. PubMed ID: 6125455
    [No Abstract]   [Full Text] [Related]  

  • 5. A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
    Nutt J
    Mov Disord; 1999; 14 Suppl 1():74. PubMed ID: 10493408
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
    Fiorentini C; Busi C; Spano P; Missale C
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S159-64. PubMed ID: 18638717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG
    Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract]   [Full Text] [Related]  

  • 9. Are there clinically significant differences between dopamine agonists.
    Stocchi F; Vacca L; Onofrj M
    Adv Neurol; 2003; 91():259-66. PubMed ID: 12442684
    [No Abstract]   [Full Text] [Related]  

  • 10. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
    Rascol O; Brefel-Courbon C; Blin O
    Therapie; 1998; 53(1):43-8. PubMed ID: 9773099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy found for Parkinson's disease dyskinesia.
    Bradbury J
    Lancet; 2003 May; 361(9370):1712. PubMed ID: 12767746
    [No Abstract]   [Full Text] [Related]  

  • 14. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion.
    Alves R; Barbosa E; Scaff M
    Mov Disord; 2006 Dec; 21(12):2267-8; author reply 2268. PubMed ID: 17078068
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug treatment of Parkinson's disease.
    Callaghan N
    Ir Med J; 1983 Aug; 76(8):364-6. PubMed ID: 6618850
    [No Abstract]   [Full Text] [Related]  

  • 17. [Drugs and indications for medical treatment in Parkinson's disease (author's transl)].
    Allain H; Van den Driessche J; Menault F; Pape D; Reymann JM; Bentue-Ferrer D
    Sem Hop; 1980 Feb 8-15; 56(5-6):277-82. PubMed ID: 6243802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New perspectives in the treatment of the motor complications associated with chronic treatment of Parkinson disease].
    Linazasoro G
    Neurologia; 1999 Oct; 14(8):393-406. PubMed ID: 10609463
    [No Abstract]   [Full Text] [Related]  

  • 20. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.